CASI Pharmaceuticals Inc
CASI1.970USD
+0.680+52.71%
Market hours （ET）Quotes delayed by 15 min
30.52MMarket Cap
LossP/E TTM
More Details of CASI Pharmaceuticals Inc Company
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Company Info
Ticker SymbolCASI
Company nameCASI Pharmaceuticals Inc
IPO dateAug 23, 2021
CEODr. Wei-Wu He, Ph.D.
Number of employees233
Security typeOrdinary Share
Fiscal year-endAug 23
Address1701-1702, China Central Office Tower 1
CityBEIJING
Stock exchangeNASDAQ Capital Market Consolidated
CountryChina
Postal code100025
Phone861065618789
Websitehttps://www.casipharmaceuticals.com/
Ticker SymbolCASI
IPO dateAug 23, 2021
CEODr. Wei-Wu He, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.52M
+11.33%
Mr. Xuebo Zeng
Mr. Xuebo Zeng
Independent Director
Independent Director
--
--
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Wei Gao
Ms. Wei Gao
General Counsel
General Counsel
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Ms. Kun Qian
Ms. Kun Qian
Vice President, Global Controller
Vice President, Global Controller
--
--
Mr. Wei (Larry) Zhang, Ph.D.
Mr. Wei (Larry) Zhang, Ph.D.
Senior Vice President
Senior Vice President
--
--
Ms. Chunhua Wang
Ms. Chunhua Wang
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Rui Zhang
Mr. Rui Zhang
Investor Relations
Investor Relations
--
--
Mr. Huang Hai
Mr. Huang Hai
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Wei-Wu He, Ph.D.
Dr. Wei-Wu He, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.52M
+11.33%
Mr. Xuebo Zeng
Mr. Xuebo Zeng
Independent Director
Independent Director
--
--
Dr. Y. Alexander Wu, Ph.D.
Dr. Y. Alexander Wu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Wei Gao
Ms. Wei Gao
General Counsel
General Counsel
--
--
Mr. Thomas Folinsbee
Mr. Thomas Folinsbee
Independent Director
Independent Director
--
--
Ms. Kun Qian
Ms. Kun Qian
Vice President, Global Controller
Vice President, Global Controller
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 25
Updated: Fri, Jul 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
He (Wei-Wu)
22.69%
Panacea Venture Healthcare Fund I LP
13.23%
Foresite Capital Management, LLC
8.58%
Sparkle Byte Ltd
6.58%
VR Adviser, LLC
6.37%
Other
42.54%
Shareholders
Shareholders
Proportion
He (Wei-Wu)
22.69%
Panacea Venture Healthcare Fund I LP
13.23%
Foresite Capital Management, LLC
8.58%
Sparkle Byte Ltd
6.58%
VR Adviser, LLC
6.37%
Other
42.54%
Shareholder Types
Shareholders
Proportion
Corporation
25.68%
Individual Investor
22.70%
Venture Capital
12.28%
Private Equity
8.58%
Hedge Fund
1.62%
Investment Advisor
0.81%
Research Firm
0.21%
Investment Advisor/Hedge Fund
0.14%
Other
27.98%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
52
11.16M
72.02%
+1.11M
2025Q1
57
11.41M
73.67%
+1.54M
2024Q4
58
11.33M
84.52%
+2.13M
2024Q3
57
9.91M
73.95%
+2.26M
2024Q2
62
7.31M
54.55%
-1.23M
2024Q1
76
7.47M
55.75%
-860.83K
2023Q4
80
7.18M
53.75%
+54.06K
2023Q3
94
6.57M
49.20%
-572.41K
2023Q2
112
6.68M
49.99%
-822.50K
2023Q1
150
6.80M
50.47%
+209.73K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
He (Wei-Wu)
3.52M
22.69%
+357.64K
+11.33%
Jun 16, 2025
Panacea Venture Healthcare Fund I LP
1.32M
8.54%
+305.00K
+29.95%
Sep 30, 2024
Foresite Capital Management, LLC
1.33M
8.58%
--
--
Mar 31, 2025
Sparkle Byte Ltd
1.02M
6.58%
--
--
Mar 21, 2025
VR Adviser, LLC
987.26K
6.37%
--
--
Mar 31, 2025
IDG Capital Partners
915.85K
5.91%
+61.97K
+7.26%
Dec 30, 2024
Wealth Strategy Holding Ltd
908.79K
5.87%
--
--
Mar 21, 2025
Woodline Partners LP
164.37K
1.06%
+64.67K
+64.88%
Mar 31, 2025
Wellington Shields Capital Management, LLC
90.89K
0.59%
+5.06K
+5.89%
Mar 31, 2025
Adar1 Capital Management LLC
47.42K
0.31%
+1.10K
+2.37%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
Date
Type
Ratio
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
May 26, 2022
Merger
10<1
